在内甲素受体中对抗剂选择性的结构基础
Junyi Hou1, Shenhui Liu2,3, Xiaodan Zhang2,3
1Cardiac Intensive Care Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Cell discovery
|July 29, 2024
概括
对内分泌素受体 (ETA和ETB) 的结构洞察力揭示了像马西坦和阿姆布里森坦这样的药物如何结合. 这项工作为设计肺动脉高血压和相关疾病的新疗法提供了框架.
科学领域:
- 结构生物学是结构生物学.
- 药理学 药理学是指药理学的学科.
- 受体激活的分子机制.
背景情况:
- 内细胞蛋白及其受体 (ETA,ETB) 对于血管平衡至关重要.
- ETA对抗剂是肺动脉高血压 (PAH) 和其他心血管/脏疾病的有效治疗方法.
研究的目的:
- 阐明内甲素受体结合和激活的分子基础.
- 为合理设计新型内甲素受体向治疗方法提供结构框架.
主要方法:
- 电子显微镜 (cryo-EM) 用于用药物 (macitentan,ambrisentan,zibotentan) 和抗体确定ETA的结构.
- 确定ETA和ETB与内甲素-1和激动剂 (BQ3020) 结合的活性状态结构.
主要成果:
- ETA与PAH药物和抗体结合的详细结构.
- 确定赋予抗体选择性的关键残留物和ETA激活机制.
- 在ETA上对抗体介导的对抗性进行皮层映射.
结论:
- 这项研究提供了对内甲素受体功能和药物相互作用的全面结构理解.
- 这些发现有助于合理设计的小分子和抗体,以治疗效益的目的是针对内分泌素受体.
相关概念视频
Drug-Receptor Interaction: Antagonist
2.8K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
149
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
149
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
559
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
559
Dose-Response Relationship: Selectivity and Specificity
6.6K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.7K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
840
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
840


